Multifaceted repurposing of flozins, glitazones, gliptins and GLP-1 agonists as potential pluritherapeutic agents

Document Type

Article

Publication Date

1-1-2020

Abstract

© RJPT All right reserved. Multifaceted repurposing of flozins, glitazones, gliptins and GLP-1 agonists as potential pluritherapeutic agents is an economic off-target substitute to molecular target based drug discovery. The author performed a Scopus database literature review of articles published on repurposing of flozins, glitazones, gliptins and GLP-1 agonists published between 2016 and 2019. Rosiglitazone repositioning for pulmonary arterial hypertension and hepatocellular carcinoma and canagliflozin repositioning for lung cancer were reported. Sitagliptin rescued memory deficits in Parkinson’s rats. Glitazones were described for Parkinson’s disease, pioglitazone enhanced hippocampal neurogenesis, decreased mortality in Parkinson’s rat model. Pioglitazone reverses traumatic brain injury. Rosiglitazone showed neuroprotective effects for both brain and eye in Parkinson’s rat model. Rosiglitazone showed reduction of glia-mediated inflammation in neurodegenerative diseases. Glitazone use was associated with decreased risk of incident PD in people with diabetes type 2. Glucagon-like peptide-1 (GLP-1) agonist has been reported to ameliorate the severity of motor symptoms associated with PD. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials with neuroprotective effects in preclinical models of Parkinson's disease.

Link to Full Text

Share

COinS